ADVFN - Advanced Financial Network.
HOME» NYSE » G » GSK Stock Price » GSK Stock News

Glaxosmithkline Share News

 Glaxosmithkline Stock Price
GSK Stock Price
 Glaxosmithkline Stock Chart
GSK Stock Chart
 Glaxosmithkline Stock News
GSK Stock News
 Glaxosmithkline Company Information
GSK Company Information
 Glaxosmithkline Stock Trades
GSK Stock Trades

AstraZeneca Needs To Replenish Drug Pipeline - Chairman

By Marta Falconi ZURICH--AstraZeneca PLC (AZN) aims to replenish its thin pipeline of new drugs through external collaborations and by buying drugs in late stages of development from other drugmakers, Chairman Leif Johansson said in an interview Tuesday. His comments come after the company announced it appointed former Roche head of pharma, Pascal Soriot, as chief executive, to succeed David Brennan, who earlier this year retired abruptly amid shareholder dissatisfaction with the company's performance. "There's a number of medicines going off patent," Mr. Johansson said. "We need to replenish them." The U.K.'s No. 2 drug maker by sales, after GlaxoSmithKline PLC (GSK), has suffered a number of expensive drug-development failures, and shown a poor track record in bringing new medicines to market, analysts say. Some of AstraZeneca's biggest drugs are facing, or will soon face, competition from low-cost generics. Mr. Johansson also said that while the pharmaceutical sector is facing challenges, there are also opportunities, such as the possibility of buying buy late-stage drugs, emerging markets and advances in science, including genome technology, which he touted as a way to learn how the human body works and possibly help find new drugs. Write to Marta Falconi at marta.falconi@dowjones.com Subscribe to WSJ: http://online.wsj.com?mod=djnwires

Stock News for Glaxosmithkline (GSK)
DateTimeHeadline
05/26/201510:35:26Report of Foreign Issuer (6-k)
05/26/201509:00:00ViiV Healthcare and CHAI Collaboration Delivers Second Milestone...
05/22/201513:00:42Report of Foreign Issuer (6-k)
05/22/201512:39:34Report of Foreign Issuer (6-k)
05/21/201517:00:06Law Firm Advising Teva Dismisses Mylan Objections
05/21/201508:05:02Following Hepatitis C, This Could Be the Next Disease Researchers...
05/19/201509:00:00New Study Shows Inner-City Asthma Care Program Reduces Student...
05/16/201511:41:03Could an HIV/AIDS Vaccine Be a Reality By the End of the Decade?
05/15/201513:31:20Report of Foreign Issuer (6-k)
05/15/201513:29:58Report of Foreign Issuer (6-k)
05/15/201513:27:23Report of Foreign Issuer (6-k)
05/14/201519:00:35Actavis Has Discussed Settling Federal Probe
05/14/201518:50:22Actavis Has Discussed Settling Federal Probe of Warner Chilcott...
05/14/201513:13:25LONDON MARKETS: FTSE 100 Finds Its Footing As Draghi Backs Eurozone...
05/14/201509:04:02How a Strong Dollar Affects Pharmaceutical Stocks
05/14/201507:24:38LONDON MARKETS: FTSE 100 Slips, With Miners, Glaxo In The Red
05/13/201509:16:21Report of Foreign Issuer (6-k)
05/13/201509:04:02Better Dividend Stock: Pfizer, Inc. or GlaxoSmithKline plc?
05/12/201511:10:43Report of Foreign Issuer (6-k)
05/12/201510:26:53Report of Foreign Issuer (6-k)

Glaxosmithkline and other New York Stock Exchange stock quotes are delayed by at least 20 minutes.
All other stock price data is delayed by at least 15 minutes unless otherwise stated.
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2007 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations

ADVFNADVFN ItalyADVFN GermanyADVFN FranceADVFN BrazilADVFN JapanADVFN UKADVFN US noad